The short answer: regulatory writing is a type of medical writing. Medical writing is the umbrella term for any professional writing about medicine and health — journal manuscripts, conference posters, slide decks for medical affairs, CME modules, patient materials, and the documents a company submits to regulators. Regulatory writing is the branch that produces that last category: Clinical Study Reports, protocols, Investigator's Brochures, safety update reports, and the submission dossiers that carry a drug or device through approval.
The confusion is real, though, and job ads make it worse. A posting titled "Medical Writer" at a pharma company or CRO usually means a regulatory writer. The same title at a medical communications agency means someone writing manuscripts and congress materials, which is a different job with a different audience, different source material, and a different career track. If you're comparing roles, ignore the title and read the document list.
This post lays out the full taxonomy, what the day-to-day actually looks like in each branch, which branches tend to pay more and why, and how realistic it is to move between them.
Why the terms get blurred
Two things drive the confusion. First, everyone in the field is a "medical writer" in the generic sense, so the umbrella term gets used for every specialty — the professional associations do it too. AMWA (the American Medical Writers Association) and EMWA (its European counterpart) both serve regulatory writers, publication writers, and med comms writers under one membership.
Second, the industry itself splits along a line that titles don't capture: documents written for regulators versus documents written for everyone else. The first group is governed by ICH guidelines and health-authority expectations; the second by journal requirements, publication ethics (GPP and ICMJE), and commercial review processes. That line — not the job title — is what determines what your working week looks like.
If you want the regulatory side in depth, start with our complete guide to regulatory writing. This post is about how it sits relative to everything else.
The types of medical writing: a taxonomy
Here is the map most working writers would recognize. It groups the branches by audience and document type, not by how heavily regulated each one is — promotional writing and accredited CME are tightly regulated too, just under different rules:
| Branch | Typical documents | Primary audience | Governing rules |
|---|---|---|---|
| Regulatory writing | CSRs, protocols, IBs, PSURs/DSURs, CERs, CTD/eCTD submission modules, briefing documents | Health-authority reviewers (FDA, EMA, PMDA, MHRA) | ICH guidelines (E3, E6(R3), E2C(R2), E2F, M4) and agency templates govern; professional guidance such as CORE Reference supports |
| Publications | Journal manuscripts, abstracts, posters, congress presentations | Clinicians and researchers | Journal style, ICMJE authorship criteria, GPP guidelines |
| Medical communications / medical affairs | Slide decks, MSL training materials, advisory board pre-reads and reports, standalone summaries | Internal field teams, KOLs, prescribers | Company review (medical-legal-regulatory), accuracy and fair-balance norms |
| Medical education / CME | Accredited education modules, needs assessments, case-based learning | Practicing clinicians earning credits | Accreditation criteria (e.g., ACCME independence rules) |
| Promotional / marketing review | Detail aids, websites, launch materials, and the medical review of all of it | Prescribers and sometimes consumers | Advertising regulations, claims substantiation, MLR review |
| Health economics (HEOR) | Value dossiers (e.g., AMCP format), payer materials, cost-effectiveness narratives | Payers, HTA bodies (e.g., NICE) | HTA submission requirements, health-economics methods |
A few notes on the boundaries. Publications and med comms overlap heavily and many agencies staff them from the same pool. HEOR writing sits closest to regulatory in rigor — it argues from data to a skeptical institutional reviewer — but the reviewer is a payer, not a health authority. And promotional review is the odd one out: many "medical writers" there spend more time reviewing claims against source data than drafting.
For what the regulatory document set actually contains at each stage of development, see our guide to regulatory documents in drug development.
What does the day-to-day actually look like?
The branches differ less in subject matter than in constraints.
Audience. A regulatory writer writes for a health-authority reviewer who is obligated to read the document and empowered to reject it. A publications writer writes for a journal editor and peer reviewers who can decline it, then for busy clinicians who skim it. A med comms writer writes for an internal audience or for KOLs in a room. A promotional writer writes for a prescriber with thirty seconds of attention. The regulator is obligated to scrutinize the full evidence base, so regulatory persuasion is disciplined and evidence-led rather than rhetorical — though journal editors and payers also demand complete evidentiary support before they are convinced.
Source material. Regulatory writing demands controlled, traceable sourcing. The core inputs are the protocol, the statistical analysis plan, and the tables/figures/listings, but relevant literature, prior reports, regulatory correspondence, and labeling can legitimately feed in too. The principle is not "nothing from outside the trial" — it is that every claim draws on an appropriate, approved source and traces cleanly back to it. Publications and med comms draw on the same trial data but lean more on published literature, and the writer has more latitude in framing. In regulatory work, that latitude is narrower by design.
Templates and structure. A CSR is built around ICH E3, which sets out the expected content and a recommended structure while allowing reorganization as long as everything stays complete and findable; a PSUR follows E2C(R2); a submission follows the CTD's five-module structure under ICH M4. The framework is largely given; the skill is filling it accurately and consistently. A manuscript follows a journal's format, but the narrative arc is yours to build. This is a real temperamental divide in the field: some writers find templates freeing (the structure is mostly solved, focus on the content), others find them stifling.
Review cycles. Everything gets reviewed, but differently. Regulatory documents go through structured internal review rounds with biostatistics, clinical, safety, and regulatory affairs, against a hard submission date. Manuscripts go through internal review, then the slower, less predictable cycle of journal peer review. Medical-affairs materials are nonpromotional and reviewed for scientific accuracy and fair balance, typically on a quick internal cycle of days; promotional pieces go through the more formal medical-legal-regulatory (MLR) review that clears commercial claims against their source data.
Timelines. Regulatory work is deadline-driven in a way little else in writing is: submission dates are commitments to health authorities, and a late DSUR can put a sponsor out of compliance, not just behind schedule. Publications timelines are often more forgiving, but congress abstract and submission deadlines can be immovable. Med comms is a steady stream of short-fuse deliverables.
Which type of medical writing pays best?
Qualitatively, regulatory and HEOR roles may command a premium over publications, med comms, and general health content — but how much depends heavily on experience, geography, and employment model (staff, contract, or agency). AMWA and EMWA publish periodic salary surveys worth checking for current, region-specific numbers.
The reasons are structural, not mysterious. First, scarcity: regulatory writing requires working knowledge of the ICH guidelines and of how agencies read documents, which takes years to build and can't be faked in a portfolio. Second, stakes: a weak manuscript gets rejected by a journal; a weak submission document delays an approval worth enormous sums per month. Employers pay for the difference in downside. HEOR pays similarly and for similar reasons — few people combine health-economics methods with writing ability, and payer decisions carry launch-level stakes.
Moving between the tracks
In practice, writers move between these tracks fairly often, and some moves tend to be easier than others.
The smoother moves, anecdotally, run toward regulatory from adjacent data-heavy work: publications writers who already interpret clinical trial results often transfer well, because the core skill — turning TFLs into accurate prose — is shared. The reverse tends to be manageable too: regulatory writers moving into publications mostly need to loosen up stylistically and learn journal and GPP conventions.
Harder moves cross the data line. Going from promotional or CME writing into regulatory usually means deliberately building clinical-data literacy first — reading protocols and SAPs, learning the document types, studying E3 and supporting guidance like CORE Reference. It's done regularly, but it tends to be a retraining project rather than a lateral step. Our guide on how to become a regulatory writer covers the practical route, including for people coming from the lab, pharmacy, or clinic rather than from another writing job.
One honest note: the tracks also select for temperament. Writers who love crafting an argument tend to stay in publications and med comms. Writers who take satisfaction in precision, traceability, and getting a 400-page document internally consistent tend to stay in regulatory. Neither is the lesser skill; they are different skills wearing the same job title.
How AI is affecting each branch differently
AI is arriving in every branch, but not in the same shape. Publications and med comms writers mostly use general-purpose AI as an assistant — summarizing literature, tightening drafts, drafting first-pass slides. That use is bounded, though, by confidentiality obligations, copyright, publication-ethics rules, and company policy on what may be put into general-purpose AI tools.
Regulatory writing lends itself to a more systematic kind of automation, because the documents are structured and their claims must trace to approved sources — a different technical problem from open-ended "help me write." That is why purpose-built tools exist for this branch; our explainer on what regulatory writing automation is covers how it differs from generic AI chat and what it means for the job.
Disclosure: Asthra drafts regulated documents in Word with sentence-level citations to writer-approved sources.
The bottom line
Regulatory writing is medical writing — the branch of it aimed at health authorities, governed by ICH guidelines, and built on structured documents with controlled, traceable sourcing. When you're weighing a job title, ask one question: who is the audience, and what documents will I produce? The answer places the role on the map faster than any title will.